The following is a summary of the Xtant Medical Holdings, Inc. (XTNT) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Xtant Medical reported strong Q2 2024 financials with revenue rising 48% year-over-year to $29.9 million.

• The company achieved adjusted EBITDA of $0.5 million, marking the fifth consecutive quarter of positive adjusted EBITDA.

• Gross margin improved slightly to 62.1%, driven by increased scale and efficiency.

• The company reaffirms full year revenue guidance of $116 million to $120 million, indicating anticipated growth of approximately 27% to 31% over 2023.

Business Progress:

• Xtant Medical continues to progress in product innovation, having introduced amniotic membrane allografts and developing the Cortera Posterior Fixation System, expecting full rollout by Q4 2024.

• The company expanded its distribution network, adding 15 new distributors this quarter.

• Planning to increase self-production to enhance profitability and reduce reliance on external suppliers, especially noted in biologics production.

Opportunities:

• The company sees opportunities in biologics through internal development and control over production.

• Expansion in the distribution network and new product lines are expected to fuel continued growth.

• Targeting acquisitions that complement existing offerings or enhance scale and capabilities, mainly in regenerative biologics and spine fixation.

Risks:

• Initial challenges in the first half of the year were mainly due to supply chain issues, which have been largely addressed.

• Cannibalization of older hardware with acquired Surgalign product lines, though strategically planned, could impact total revenue streams from original products.

More details: Xtant Medical IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.